A single infusion of VX-880 offers the potential to transform type 1 diabetes management. This study was presented at the European Association for the Study of Diabetes Congress 2025. In this phase 1/2 study, 12 adults with impaired hypoglycemia awareness and multiple severe hypoglycemic episodes received VX-880 under standard immunosuppression. At baseline, all participants had undetectable fasting C-peptide and frequent hypoglycemia.

By day 90, all participants demonstrated engraftment with glucose-responsive C-peptide production, which persisted through 12 months. Hemoglobin A1c decreased from a mean of 7.8% at baseline to 6.0% at Month 12, and time in range improved from 49.5% to 93%. Severe hypoglycemic episodes were eliminated after Day 90, and exogenous insulin use decreased by a mean of 92%, with 83% of participants no longer requiring insulin at one year.

Adverse events were generally mild or moderate, with no VX-880-related serious events. Two unrelated deaths were previously reported. These results highlight VX-880’s potential as a durable, allogeneic islet cell therapy capable of restoring glycemic control and reducing the burden of insulin therapy in type 1 diabetes.